UniQure NV shares soared after the company announced it will be able to seek US approval for its Huntington’s disease gene therapy before conducting a new study, a dramatic reversal that shows the Trump administration is relaxing its previous hard-line stance on drug reviews.
UniQure NV shares soared after the company announced it will be able to seek US approval for its Huntington’s disease gene therapy before conducting a new study, a dramatic reversal that shows the Trump administration is relaxing its previous hard-line stance on drug reviews.
<iframe src="https://statesidedaily.com/embed/cluster/13ef3dc6d7078d8918abf9b9597762ad26ce1c47" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="UniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy"></iframe>
